Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Wednesday. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.33 on Wednesday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $61.64 million, a PE ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $14.08. The stock’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.37.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.